STOCKHOLM, Sept. 11, 2023 /PRNewswire/ -- Medivir AB (NASDAQStockholm:MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announced today that Medivir's partner Tango Therapeutics has received FDA clearance on its Investigational New Drug application for TNG348.
Read more at prnewswire.comMedivir's Partner Tango Therapeutics received FDA clearance to start the TNG348 phase 1/2 clinical study
PR Newswire - Press Release
All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here